BioXcel Therapeutics, Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
BioXcel Therapeutics filed an 8-K on August 28, 2026 disclosing Item 1.01 (Material Definitive Agreement) and Item 1.03 (Bankruptcy or Receivership). The filing document itself does not contain the specific terms, counterparties, dollar amounts, or dates of the agreement or bankruptcy proceeding—only the section headers are listed. Critical details required to assess impact are absent from this filing extract.
Why this rating
Bankruptcy/receivership disclosure plus material agreement at $11M market-cap company signals existential threat. Event is potentially business-changing regardless of missing specifics.
Extracted items
- 1.01 material agreement
- 1.03 bankruptcy
Tradability signal
NO TRADE
No trade: price $0.43 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.32 ▼ 25.85% | at our read · backfill $0.43 | +10 min · backfill $0.40 ▼ 8.48% | +30 min · backfill $0.39 ▼ 8.96% | +1 hr · backfill $0.31 ▼ 28.14% | +4 hrs · backfill $0.20 ▼ 53.98% |
The stock had already moved +34.86% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.